Alerts will be sent to your verified email
Verify Email
BROOKS
Positive for this company
Neutral for this company
Negative for this company
Insufficient data to analyse
Brooks Laboratories Limited focuses on critical care products including Beta Lactam, Cephalosporin, and General Dry powder Injectables. It provides a diverse product portfolio for multiple companies.
Brooks Laboratories major competitors are Ambalal Sarabhai Ent, Lyka Labs, Vaidya Sane Ayur Lab, Coral Laboratories, Kimia Biosciences, Panchsheel Organics, Alpa Lab.
Market Cap of Brooks Laboratories is ₹204 Crs.
While the median market cap of its peers are ₹159 Crs.
Brooks Laboratories seems to be financially stable compared to its competitors.
The probability of it going bankrupt or facing a financial crunch seem to be lower than its immediate competitors.
| 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | |||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Annual Report | FY26 | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 | FY12 | FY11 | FY10 | ||
| Earnings Release | Dec | ||||||||||||||||||
| Investor Presentation | |||||||||||||||||||
| Conference Call | |||||||||||||||||||
|
Conference Call SummaryCon Call Summary
Powered by Gemini
|
